Bellicum Pharmaceuticals to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

Rhea-AI Summary

Bellicum Pharmaceuticals (NASDAQ:BLCM) announced that CEO Rick Fair will participate in the H.C. Wainwright 23rd Annual Global Investment Conference virtually. A pre-recorded presentation will be available on-demand starting September 13, 2021, at 7 a.m. ET, and will remain accessible for 90 days via Bellicum’s website. Bellicum focuses on developing controllable cellular immunotherapies for cancer, with products like GoCAR-T® designed to enhance CAR-T cell therapy efficacy by overcoming immune inhibitors.

HOUSTON, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that Rick Fair, President and CEO, will participate in the H.C. Wainwright 23rd Annual Global Investment Conference (Virtual). A pre-recorded presentation will be available to view on-demand beginning at 7 a.m. ET / 4 a.m. PT on September 13, 2021 and will remain accessible for 90 days in the Events and Presentations section of the Bellicum website.

About Bellicum Pharmaceuticals

Bellicum is a clinical stage biopharmaceutical company striving to deliver cures through controllable cell therapies. The company’s next-generation product candidates are differentiated by powerful cell signaling technologies designed to produce more effective CAR-T cell therapies. Bellicum’s GoCAR-T^® product candidates, BPX-601 and BPX-603, are designed to be more efficacious CAR-T cell products capable of overriding key immune inhibitory mechanisms. More information about Bellicum can be found at www.bellicum.com. 

Source: Bellicum Pharmaceuticals

Investors:
Robert H. Uhl
Managing Director
Westwicke ICR
858-356-5932
Robert.uhl@westwicke.com

 

FAQ

When will Rick Fair's presentation at the H.C. Wainwright conference be available for viewing?

Rick Fair's pre-recorded presentation will be available on-demand starting September 13, 2021, at 7 a.m. ET.

How long will the presentation by Bellicum Pharmaceuticals remain accessible?

The presentation will remain accessible for 90 days.

What is Bellicum Pharmaceuticals known for?

Bellicum Pharmaceuticals is known for developing novel, controllable cellular immunotherapies for cancer.

What are GoCAR-T® product candidates?

GoCAR-T® product candidates, such as BPX-601 and BPX-603, are designed to produce more effective CAR-T cell therapies.

What technologies does Bellicum use to enhance its therapies?

Bellicum employs powerful cell signaling technologies to overcome key immune inhibitory mechanisms.